Try our beta test site

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

This study has been completed.
Sponsor:
Collaborator:
Exelixis
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01866293
First received: May 28, 2013
Last updated: February 8, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 18, 2016
  Primary Completion Date: August 18, 2016 (Final data collection date for primary outcome measure)